SOURCE: Solos Endoscopy, Inc.

March 30, 2012 09:47 ET

Solos Endoscopy Reduces Net Loss by More Than $688,000

Company Posts Year End Financials for Period Ending December 31, 2011

BOSTON, MA--(Marketwire - Mar 30, 2012) - Solos Endoscopy, Inc. (PINKSHEETS: SNDY) is pleased to announce that the Company has posted its Year End Financial Statements for Period Ending December 31, 2011 on OTC Markets (http://www.otcmarkets.com/stock/SNDY/financials). In 2011, Solos Endoscopy consummated agreements, which resulted in the forgiveness of $457,471 in debt for the Company. The signed settlement agreement and new consulting agreement resulted in a reduction of ongoing expenses by approximately $40,000 per quarter that will carry over into 2012. As a result, Solos Endoscopy was able to reduce its Net Loss by more than $688,000.

Throughout the year, Solos has focused its R & D efforts into the design and development of new modifications to its endoscopic instrument lines to accommodate the continual advances in Laparoscopic surgical procedures. The significant advances over the past several years have led to a number of advantages to the patient with laparoscopic surgery versus an open procedure (laparotomy). These advantages include reduced pain due to smaller incisions and hemorrhaging, and shorter recovery time.

The demand for endoscope services is increasing due to an increase in the aging and chronically ill population worldwide. Advancements in endoscopic technologies and inclusion of various types of lighting sources, video cameras, real-time conversion of data into three-dimensional images are also driving this market. Endoscopy procedures have become highly effective in the diagnosis, treatment, and management of cancer patients. Many now consider endoscopy to have become the gold standard for cancer diagnosis and treatment, as well as for many other medical conditions.

The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation. The Solos MammoView® system is currently in use at various teaching hospitals across the United States. From July through November, mammary ductoscopy instrument sales accounted for approximately 40% of the total sales for the period.

Solos Endoscopy generated revenues during the year ended December 31, 2011 in the amount of $328,612 versus $429,473 for the year ended December 31, 2010. The Company's net loss during the year ended December 31, 2011 was $503,787 versus a loss of $1,192,481 for the year ended December 31, 2010. Therefore the Company, due to a reduction in consulting services costs of $200,000, a decrease in general and administrative expenses of $131,658 and forgiveness of debt in the amount of $457,471 for the year ended December 31, 2011, has significantly reduced its loss from operations for the year ended December 31, 2011, as compared to the year ended December 31, 2010, in the amount of $688,694.

"Solos management has made a real effort to reduce debt and position the Company for profitability. By working with its various creditors, management believes the Company can be virtually debt free by the 2nd quarter of 2012," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact Information